Propensity score-matched study reveals TACE-HAIC significantly improves survival in unresectable HCC, suggesting a superior approach compared to TACE.
Key Points
TACE-HAIC significantly increased objective response to 74.0% compared to 58.4% for TACE, indicating better treatment effectiveness.
Median progression-free survival for patients treated with TACE-HAIC was 12.3 months, compared to 7.4 months with TACE, highlighting its efficacy.
Patients in Barcelona Clinical Liver Cancer stage C experienced notably longer overall survival in the TACE-HAIC group, demonstrating treatment benefits.
TACE-HAIC therapy exhibited an acceptable safety profile with fewer severe adverse events compared to TACE alone, supporting its clinical use.